Literature DB >> 6810757

Activities of various beta-lactams and aminoglycosides, alone and in combination, against isolates of Pseudomonas aeruginosa from patients with cystic fibrosis.

R K Scribner, M I Marks, A H Weber, M M Tarpay, D F Welch.   

Abstract

The inhibitory and bactericidal activities of carbenicillin, ticarcillin, moxalactam, cefoperazone, azlocillin, piperacillin, ceftazidime, and three aminoglycosides, alone and in various combinations, were determined against 60 isolates of Pseudomonas aeruginosa from the sputum of patients with cystic fibrosis. Ceftazidime was the most active beta-lactam, with minimum inhibitory and bactericidal concentrations for 90% of isolates of 4 micrograms/ml. Moxalactam was the least active of the new beta-lactams, with activity equivalent to that of carbenicillin; each had a minimum inhibitory concentration for 90% of isolates of 64 micrograms/ml and a minimum bactericidal concentration for 90% of isolates of 128 microgram/ml. All combinations of an aminoglycoside plus a beta-lactam showed favorable inhibitory effects. Combinations of beta-lactams showed mostly addition or indifference. Although little antagonism was seen with combinations of beta-lactams or with aminoglycoside-beta-lactam combinations, no consistent advantage of beta-lactam combinations was demonstrated in vitro. These results suggest several single drugs and combinations that merit clinical evaluation in cystic fibrosis patients with Pseudomonas pulmonary infections.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6810757      PMCID: PMC182049          DOI: 10.1128/AAC.21.6.939

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  15 in total

1.  The concentration of tobramycin in bronchial secretions.

Authors:  M R Alexander; E M Berglund; J E Kasik; A Fox; W M Chinn
Journal:  Chest       Date:  1979-06       Impact factor: 9.410

2.  Carbenicillin and gentamicin: pharmacologic studies in patients with cystic fibrosis and pseudomonas pulmonary infections.

Authors:  M I Marks; R Prentice; R Swarson; E K Cotton; T C Eickhoff
Journal:  J Pediatr       Date:  1971-11       Impact factor: 4.406

3.  Comparative study of anti-pseudomonas activity of azlocillin, mezlocillin, and ticarcillin.

Authors:  L Coppens; J Klastersky
Journal:  Antimicrob Agents Chemother       Date:  1979-03       Impact factor: 5.191

4.  In vitro activity of piperacillin compared with that of carbenicillin, ticarcillin, ampicillin, cephalothin, and cefamandole against Pseudomonas aeruginosa and Enterobacteriaceae.

Authors:  P P Shah; D J Briedis; H G Robson; J P Conterato
Journal:  Antimicrob Agents Chemother       Date:  1979-03       Impact factor: 5.191

5.  Activity of newer aminoglycosides and carbenicillin, alone and in combination, against gentamicin-resistant Pseudomonas aeruginosa.

Authors:  M I Marks; S Hammerberg; G Greenstone; B Silver
Journal:  Antimicrob Agents Chemother       Date:  1976-09       Impact factor: 5.191

6.  Concentrations of gentamicin in bronchial secretions after intramuscular and endotracheal administration.

Authors:  W Odio; E Van Laer; J Klastersky
Journal:  J Clin Pharmacol       Date:  1975-07       Impact factor: 3.126

7.  Bronchial secretion levels of amikacin.

Authors:  W L Dull; M R Alexander; J E Kasik
Journal:  Antimicrob Agents Chemother       Date:  1979-12       Impact factor: 5.191

8.  Activities of new beta-lactam antibiotics against isolates of Pseudomonas aeruginosa from patients with cystic fibrosis.

Authors:  A S Prince; H C Neu
Journal:  Antimicrob Agents Chemother       Date:  1981-10       Impact factor: 5.191

9.  Treatment of pulmonary infections in patients with cystic fibrosis: a comparative study of ticarcillin and gentamicin.

Authors:  M F Parry; H C Neu; M Merlino; P F Gaerlan; C N Ores; C R Denning
Journal:  J Pediatr       Date:  1977-01       Impact factor: 4.406

10.  Comparative susceptibilities of Pseudomonas aeruginosa to 1-oxacephalosporin (LY 127935) and eight other antipseudomonal antimicrobial agents (old and new).

Authors:  V L Yu; R M Vickers; J J Zuravleff
Journal:  Antimicrob Agents Chemother       Date:  1980-01       Impact factor: 5.191

View more
  20 in total

Review 1.  Cystic fibrosis, pathophysiological and clinical aspects.

Authors:  H J Neijens; M Sinaasappel; R de Groot; J C de Jongste; S E Overbeek
Journal:  Eur J Pediatr       Date:  1990-08       Impact factor: 3.183

2.  Comparison of antimicrobial efficacy of a fixed dose combination of ceftazidime + sulbactam with ceftazidime and sulbactam alone against five bacteria.

Authors:  S M Shrivastava; S K Shukla; M Chaudhary
Journal:  Folia Microbiol (Praha)       Date:  2009-11-24       Impact factor: 2.099

3.  In vitro activity of new antimicrobial agents against Pseudomonas aeruginosa isolates from cystic fibrosis patients.

Authors:  A M Horrevorts
Journal:  Eur J Clin Microbiol       Date:  1987-06       Impact factor: 3.267

4.  Changing susceptibility of Pseudomonas aeruginosa isolates from cystic fibrosis patients with the clinical use of newer antibiotics.

Authors:  J A Bosso; J E Allen; J M Matsen
Journal:  Antimicrob Agents Chemother       Date:  1989-04       Impact factor: 5.191

5.  Synergistic activity of aminoglycoside-beta-lactam combinations against Pseudomonas aeruginosa with an unusual aminoglycoside antibiogram.

Authors:  R B Clark; C B Pakiz; M K Hostetter
Journal:  Med Microbiol Immunol       Date:  1990       Impact factor: 3.402

6.  In vitro comparison of Pseudomonas aeruginosa isolates with various susceptibilities to aminoglycosides and ten beta-lactam antibiotics.

Authors:  D H Wu; A L Baltch; R P Smith
Journal:  Antimicrob Agents Chemother       Date:  1984-04       Impact factor: 5.191

7.  Ceftazidime compared with gentamicin and carbenicillin in patients with cystic fibrosis, pulmonary pseudomonas infection, and an exacerbation of respiratory symptoms. British Thoracic Society Research Committee.

Authors: 
Journal:  Thorax       Date:  1985-05       Impact factor: 9.139

8.  Antipseudomonal therapy in cystic fibrosis: aztreonam and amikacin versus ceftazidime and amikacin administered intravenously followed by oral ciprofloxacin.

Authors:  U B Schaad; J Wedgwood-Krucko; K Guenin; U Buehlmann; R Kraemer
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1989-10       Impact factor: 3.267

9.  Correlation between activity of beta-lactam agents in vitro and bacteriological outcome in acute pulmonary exacerbations of cystic fibrosis.

Authors:  J L Gaillard; P Cahen; C Delacourt; C Silly; M Le Bourgeois; C Coustère; J de Blic; G Lenoir; P Scheinmann
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1995-04       Impact factor: 3.267

10.  In vitro activity of aztreonam in combination with newer beta-lactams and amikacin against multiply resistant gram-negative bacilli.

Authors:  M A Buesing; J H Jorgensen
Journal:  Antimicrob Agents Chemother       Date:  1984-02       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.